Siremadlin
As of the edition of 20 October 2026, Siremadlin is a small molecule: stopped in 2024; acts on MDM2 and TP53.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 14, 6 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Eye; Lungs and airways; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route A because of this drug.
Companies on route A for this drug
In the product1 company-target row is on route A because of Siremadlin.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 6 | 0 | 3 |
| Phase 2 | 5 | 0 | 2 | 3 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novartis | Lead sponsor of trials | 2014 to now |